The deal is the first contract signed by Europe's Inclusive Vaccines Alliance (IVA), a group formed by France, Germany, Italy and the Netherlands to secure vaccine doses for all member states as soon as possible. China, Brazil, Japan and Russian Federation have also expressed interest, he said. "We believe in the power of cooperation, and we're also hedging our bets because you never know which horse is going to win the race".
The new public health advice from Dr. David Williams means physical distancing does not need to be practised between members of the same so-called "social circle". Ottawa Public Health reported nine new confirmed cases of COVID-19 and no additional deaths Friday. That includes the Greater Toronto and Hamilton Area, the U.S.
They're following contacts. And they're not finding secondary transmission onward . Van Kerkhove, citing disease-modelling studies , clarified on Tuesday (June 9) that some people do not develop symptoms, but can still infect others. The U.S. Centers for Disease Control and Prevention says asymptomatic people can spread coronavirus and continues to recommend people wear face masks in public places where social distancing is not possible, such as grocery stores and pharmacies.
A CDC spokesperson in an email said health experts are certain that "some people without symptoms may be able to spread the virus". Kerkhove stated that studies show that about 16% of the population may be asymptomatic . And Van Kerkhove was trying to say this in the context of - if we could just go after the symptomatic cases, contain those, we can bring these outbreaks under control.
Van Kerkhove said during a press conference on Tuesday. "I was responding to a question at the press conference, I wasn't stating a policy of World Health Organization or anything like that", Kerkhove said Tuesday (watch above, at the beginning of the video).
The company informed via a press release that they have been able to further accelerate the clinical development of the investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. The full details of that study aren't available yet; that will soon be published by Moderna's collaborators, a team of scientists at the National Institute of Allergy and Infectious Diseases.